Therma Bright Inc. (TSXV:THRM), (“Therma Bright” or the “Company”), a progressive medical device technology company announces, further to its press release on January 8, 2018 outlining results indicating effectiveness of its TherOZap technology at inhibiting the Zika virus, that the Company has engaged a top research laboratory made up of virology experts to further test the TherOZap technology against the Zika virus. The research group collaborates with and has access to other virology research experts around the world.
Further to the Company’s press release on October 1st, 2018, the Company has completed several improvements to the TherOZap technology prototype including certain advancements to the technology and features that make the prototype easier to use and test by researchers compared to the previous version. The Company expects the receipt of final prototypes over the next 10 days at which time the prototypes will be sent to the researchers to initiate the next round of testing. Testing is expected to last several months.
The Company will follow up with additional testing, providing efficacy of the TherOZap technology during the initial tests against the Zika virus, with further in-vitro testing of the Zika virus or other mosquito borne diseases to be followed up by in-vivo testing if warranted.
The Dengue, Zika and West Nile viruses are spread by the same mosquito which is known as the Aedes Aegypti mosquito. The Aedes Aegypti mosquito is known as a prolific daytime biter which often makes it harder for people to protect themselves after an infectious bite. Therma Bright hopes to prove that the TherOZap technology will be effective as a second line of defense, after being bitten by a mosquito, against the Zika virus. Once the TherOZap technology proves effective, the Company expects to extend the prototype improvements to Therma Bright’s final commercial device with an aim to market any claims as a result of successful testing on packaging and Continue Reading